AIDS treatment activists - May, p. 108; July, p. 171; Nov., p. 298
All the Virology on the WWW - Feb., p. 43
animal models - Nov., p. 301; May, p. 98
approvals, European Union - Mar., p. 74; Aug., p. 202; Sep., p. 235; Nov., p. 298; Dec., p. 331
approvals, FDA - Feb., p. 33, 34; Mar., p. 65, 66; Apr., p. 97, 98, 104; May, p. 107; June, p. 129, 139; July, p. 161, 163; Aug., p. 203; Sep., p. 236; Oct., p. 270; Nov., p. 301; Dec., p. 321, 322
approvals, Peoples Republic of China - Sep., p. 229
approvals, U.K. - Mar., p. 72
clinical trials - Feb., p. 36, 37, 38, 39, 40, 41; Mar., p. 68, 72, 73, 74; Apr., p. 98, 100, 101, 102, 103, 104, 105; May, p. 97, 101, 102, 103, 104, 106, 107; June, p. 131, 132, 133, 135, 136, 137, 138, 140; July, p. 161, 163, 164, 166, 167, 168, 169, 170, 170, 172; Aug., p. 193, 194, 196, 197, 198, 199, 200, 201, 202, 203; Sep., p. 225, 226, 227, 228, 229, 230, 231, 235; Oct., p. 257, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271; Nov., p. 289, 290, 291, 292, 293, 295, 296, 297, 298, 299; Dec., p. 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 334
Collaborative Research & Development Agreements (CRADAs) - June, p. 133; Oct., p. 257, 260
corporate linkages - Feb., p. 39; Mar., p. 68, 72, 73; Apr., p. 106; May, p. 102, 105; July, p. 169, 170, 173; Aug., p. 195, 201, 202; Sep., p. 231, 232, 234, 235; Nov., p. 293, 297, 300; Dec., p. 329, 330
corporate mergers/acquisitions - Apr., p. 103, 106; June, p. 138; Aug., p. 200; Sep., p. 234; Nov., p. 297; Dec., p. 331, 335
databases - Aug., p. 205
drug supply problems - Nov., p. 299
expanded access - Mar., p. 71; Apr., p. 10; Sep., p. 234; Nov., p. 298
FDA reviews - Mar., p. 68, 70; June, p. 139
Germany - Mar., p. 73
Hepatitis C Information and Support - Feb., p. 43
HIV progression - June, p. 135
HIV reservoirs, throat - June, p. 134
immune activation - May, p. 102
informed consent - Nov., p. 296
Internet mailing lists - May, p. 108
Internet Web sites - Feb., p. 43; May, p. 108; June, p. 140, 141; July, p. 173; Aug., p. 205; Dec., p. 334
large-scale trials, HIV vaccines - Aug., p. 201
licensing - Feb., p. 44, 45; Mar., p. 79; May, p. 105, 107, 108, 109; June, p. 133, 135, 141, 142; July, p. 168, 169, 170, 173, 174; Aug., p. 195, 196, 199; Sep., p. 232, 234, 235, 238; Oct., p. 266, 269, 272; Nov., p. 297, 298, 302; Dec., p. 331, 335
new viruses - Mar., p. 73; Aug., p. 196, 198
news coverage, HIV - Sep., p. 237
patent disputes - Feb., p. 43, 44; Mar., p. 78; Apr., p. 107; May, p. 109; Aug., p. 205; Sep., p. 238; Nov., p. 301, 302; Dec., p. 335
pricing issues - Feb., p. 43; May, p. 99; Aug., p. 200; Nov., p. 298
product recalls - Dec., p. 332
product sales - May, p. 99, 107; June, p. 38; Aug., p. 205
production plants - Aug., p. 200; Oct., p. 266
scientific misconduct - May, p. 107
screening/drug design - Apr., p. 101, 106; May, p. 102, 105; July, p. 173; Aug., p. 201; Sep., p. 234; Oct., p. 263, 270; Nov., p. 299, 300
securities fraud - Sep., p. 236; Oct., p. 269
trademark disputes - Oct., p. 269
vaginal transmission - June, p. 133, 137; Oct., p. 267